Liquidia (LQDA) Q1 2026: Earnings Snapshot

Liquidia (LQDA) has just posted a punchy Q1 2026 print, with revenue of US$132.9 million and basic EPS of US$0.60, supported by net income of US$52.9 million. The company has seen revenue move from US$3.1 million and a loss of US$38.4 million in Q1 2025, through US$2.9 million and a loss of US$38.5 million in Q4 2024, to US$132.9 million and net income of US$52.9 million in the latest quarter. Over the same period, TTM EPS has shifted from a loss of US$1.63 in Q4 2024 to a profit of US$0.26 in Q1 2026, setting up a story where margins are now firmly in focus for investors assessing how durable this profitability profile really is.

See our full analysis for Liquidia.

With the headline numbers on the table, the next step is to see how this earnings turn lines up with the widely followed growth and risk narratives around Liquidia and where the latest results start to challenge those stories.

TTM swing from US$136.6m loss to US$22.3m profit

• On a trailing twelve month view, net income moved from a loss of US$136.6 million in Q1 2025 to a profit of US$22.3 million in Q1 2026, while TTM EPS shifted from a loss of US$1.68 to a profit of US$0.26 over the same period.
• Bulls point out that moving into profitability lines up with their view that YUTREPIA and the broader treprostinil platform can support higher margins over time, yet:
  • They reference forecasts for earnings growth of about 30.2% per year and revenue growth of about 24.9% per year, which are assessed against this US$288.1 million TTM revenue base rather than the much smaller revenue levels seen a year earlier.
  • They also highlight that bullish scenarios assume profit margins eventually settling above 40%, so investors can compare that to the current TTM profit of US$22.3 million to judge how far along the margin story is.

Bulls argue this kind of earnings shift is exactly what long term holders were waiting for, and that the latest narrative shows how they think it could continue: 🐂 Liquidia Bull Case

Q1 2026 profit of US$52.9m tests bearish caution

• In the latest single quarter, Liquidia reported net income of US$52.9 million in Q1 2026 compared with a reported loss of US$41.6 million in Q2 2025, with quarterly revenue over that span ranging from US$8.8 million to US$132.9 million.
• Bears worry that early YUTREPIA demand could be front loaded and that future revenue might not keep pace with current expectations, and the recent results give them a few pressure points to watch:
  • They flag that bearish scenario work still allows for annual revenue growth of around 100.2% over the next three years, yet that view is paired with only modest margins of about 4.2%, so a US$52.9 million quarterly profit puts the current margin picture ahead of that cautious path for now.
  • They also point out that even under these cautious assumptions, the business would need to support a relatively high future P/E, so the size and consistency of profits like this quarter become central to whether that level of valuation risk feels acceptable.

Skeptics suggest the recent jump in profit might prove harder to sustain than bulls expect, and the cautious narrative lays out the scenarios they focus on: 🐻 Liquidia Bear Case

Rich 17.5x P/S against US$56.60 share price

• The stock trades on a P/S of 17.5x versus a peer average of 7.4x and a US Pharmaceuticals industry average of 4.8x, while the current share price of US$56.60 also sits far below the DCF fair value figure of US$297.32.
• What stands out is how this valuation mix creates a tension between bullish and bearish views, using the same data points:
  • Supporters of the bullish case see the low share price versus the US$297.32 DCF fair value and the shift to a US$22.3 million TTM profit as signals that the market may be underpricing potential cash flows, even with a higher than average P/S.
  • On the other hand, cautious investors highlight the 17.5x P/S, the recent share price volatility, and the reported insider selling in the past three months as reasons to question whether current expectations already bake in a lot of good news despite that DCF gap.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Liquidia on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

With sentiment clearly split between opportunity and risk, now is a good time to look through the numbers yourself and decide what really matters for your portfolio. You can start with 3 key rewards and 2 important warning signs

See What Else Is Out There

Liquidia combines a rich 17.5x P/S multiple, recent share price volatility, and insider selling, which leaves some investors uneasy about valuation risk and future consistency.

If that mix of high expectations and uncertainty feels a bit too intense, you can quickly compare it with companies screened for 69 resilient stocks with low risk scores to find ideas that may better match your comfort level.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.